Application Deadline
February 29, 2020

Senior Molecular Biologist / Next-Generation Sequencing

Today, there is a need for more accurate and personalized RNA-based cancer diagnostics. RNA visualization and sequencing are an integrated part of R&D programs in the pharmaceutical industry, and are increasingly used at cancer centers, institutes and hospitals to provide more accurate diagnosis and subsequent personalized treatment regimens for patients.

Our biotech company, MultiplexDX, aims to drastically increase the number of cancer survivors through personalized diagnostics that lead to tailored, effective, and life-saving treatment. We want to bring to market a reliable, accurate, quantitate, cost-effective, and multiplexed diagnostic test for cancer, which can accurately identify and quantify cancer biomarkers in human tissues.

The position

We are looking for an experienced Senior Molecular Biologist Next-Generation Sequencing to take the lead in planning, conducting, and optimizing RNA-based next-generation sequencing experiments.

In this multifaceted role, you will help advance our next pipeline of designed diagnostic products, solve technical obstacles, test different concepts in the laboratory, read scientific papers, track R&D costs, study patents, and generate new ideas in collaboration with our team of innovative Molecular Biologists.

You will report to the Director of Research & Development and Chief Operating Officer and be based at the headquarters in Bratislava, Slovakia.

MultiplexDX received an EIC Accelerator grant, which guarantees two years of funding for this position with the possibility of an extension.


  • Plan, conduct, and optimize RNA-based next-generation sequencing experiments;
  • Perform other molecular biology techniques, including RNA extraction/purification, PCR, qPCR, RNA/small RNA NGS library preparation, RNA quality control (NanoDrop™, Qubit™, Bioanalyzer/Tapestation), gel electrophoresis, etc.;
  • Operate and maintain laboratory & analytical equipment;
  • Generate new concepts and ideas in collaboration with the team;
  • Test concepts in the laboratory;
  • Document experimental work, analyze data, document and present results;
  • Prepare written methods and SOPs;
  • Evaluate and document the new product or method;
  • Present research findings in manuscripts, at conferences, and to potential partners;
  • Map, document, and navigate through IPR;
  • Report on freedom to operate, technical risks, strengths, and cost estimations;
  • Communicate with partners and customers to use feedback in development;
  • Manage and mentor research associates;
  • Help to set the company’s strategic direction in terms of cancer diagnostics area of interest;
  • Stay abreast of recent developments in RNA NGS and their applications in clinical diagnostics.


  • PhD in Molecular Biology (or related field) with extensive training and practical laboratory experience in next-generation sequencing;
  • MSc degree holders will be considered if they can demonstrate significant experience;
  • 2 years hands-on laboratory experience with RNA (in particular small RNA) library preparation for next-generation sequencing and other molecular biology techniques (PCR, qPCR, gel electrophoresis) from biotech or similar industry is preferred;
  • Experience in bioinformatics or knowledge of NGS bioinformatic workflows is an advantage;
  • Ability to work independently as well as part of a multidisciplinary team is essential;
  • Excellent analytical and systematic troubleshooting skills;
  • Strong creative skills and out-of-the-box thinking;
  • Demonstration of goal-oriented, hands-on, and innovative approach to problem solving;
  • Excellent written and oral communication skills (English is our working language);
  • Excellent organizational and reasoning skills are a must;
  • Experience reading and writing patent applications is preferred.

We offer

We offer a great career with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or simply looking to contribute to a small, hard-working organization with the ambition to make a difference.

You will be offered the opportunity to spearhead the next ground-breaking diagnostic technologies involving RNA-based next-generation sequencing.

The job will be challenging and rewarding at the same time. You will have world class colleagues, flexible working hours, 5 weeks of paid holiday, and a negotiable salary commensurate to your qualifications (starting from €2000/month). This position will be funded for at least two years with the possibility of an extension under a recently awarded EIC Accelerator grant.

Application deadline

Application deadline is February 29th, 2020. Please send the application including your CV or resume with the names of 3 references and a cover letter to

Your application will be treated in accordance with our policies for processing of personal data and the General Data Protection Regulation of the EU.


MultiplexDX’s diagnostic products combine specific, precise, automated, high-throughput, multiplexed and quantitative RNA visualization and sequencing to come up with a specific“barcode” for each cancer, which suggests a unique, personalized treatment strategy. In MultiplexDX’s diagnostic tests, multiplexing stands for cross-validating test results by using two independent perspectives, visualization and sequencing. This multiplexed platform provides the most accurate clinical parameters of a patient’s cancer profile, which enables an oncologist to make an evidence-based decision and target treatment quickly, directly, and more accurately.

For additional information, please contact

Peter Kilian
Ilkovičova 8
84104 Bratislava, Slovakia

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter